Stock Analysis

Fast Track is a process designed to facilitate development and expedite review of drugs for serious conditions thatFillan unmet medical need. The announcement says it facilitates more frequent engagement with the FDA and may enable expedited review of the planned new drug application (NDA), …

Advanced Cosmeceuticals Pty Ltd was appointed as Tissue Repair's distributor for TR Pro+ in the Australian and New Zealand aesthetic markets in September 2025, so the arrangement lasted roughly a year. The company says it has determined that returning to a direct distribution model …

Each animal received Optimatrix in one eye, left in full without washing out, and a sham balanced-salt procedure in the other eye, removed as normal. The company says that even with 100% of the product remaining inside the eye, intraocular pressure returned to pre-operative …

The FDA will table written responses on Vectus's proposed development program for VB0004 in IPF. The responses are expected by mid-November 2026. Granting the meeting request is a procedural step and not an assessment of the program, and the company has not yet submitted …

The partnership follows the Phase II in-vitro platelet study conducted with the United States Army Institute of Surgical Research, announced on 22 May 2026. In that study a 3% DMSO no-wash protocol achieved 94.4% mean post-thaw platelet recovery using Vitrafy's cryopreservation ecosystem. The company …

Revenue and other income rose 30.63% to $4,839,901. The loss after income tax attributable to members was $10,610,137 compared with $10,702,271 in FY25, a reduction of 0.86%. The loss per share was 0.58 cents against 0.77 cents, reflecting a larger share count. The company …

Against the prior corresponding period, revenue was up $1.7 million, or 4.8%, EBITDA was up $1.01 million, or 197.5%, and operational expenditure was down $685,000, or 9.5%. The release does not state absolute EBITDA or revenue figures, though it describes the company's focus as …